Traditional Chinese medicine stocks have changed frequently, and this pharmaceutical company has risen again

In recent years, both the national and local levels have begun to issue a series of favorable policies to promote the high-quality development of
traditional Chinese medicine undertakings and industries.
In this context, while the prospects of the traditional Chinese medicine market are promising, traditional Chinese medicine stocks are also ushering in a sharp rise
.
It is understood that since the beginning of this year, the A-share traditional Chinese medicine sector has risen significantly
.
Relevant data show that from the beginning of 2021 to the close of trading on August 3, the stock prices of 73 listed Chinese medicine companies have risen by an average of 14.
61%.

Recently, the traditional Chinese medicine sector has been changing frequently, and many individual stocks have also ushered in a rapid rise
in stock prices.
Among them, Teyi Pharmaceutical's performance is very eye-catching
.
According to the data, Teyi Pharmaceutical is mainly engaged in the research and development, production and sales of proprietary Chinese medicines, chemical preparations and
chemical APIs.
Since November, the stock price of Teyi Pharmaceutical has risen particularly significantly, and the stock price has doubled within the month, reaching an increase of 101%, with a total market value of 6.
129 billion yuan
.
It is worth mentioning that the stock has risen 11 times
in the past year.
Last week, Teyi Pharmaceutical also gained a total of 3 limit increases, an increase of 49.
38%.

According to the data of the after-market Dragon and Tiger List on November 18, the number of seats in the business department on the list was 307 million yuan in the whole day, accounting for 30.
4%
of the total transaction amount on the day.
Among them, the purchase amount was 162 million yuan and the selling amount was 145 million yuan, with a total net purchase of 17.
4474 million yuan
.
Today, Teyi Pharmaceutical has ushered in a limit increase
.
It is reported that there are four main reasons for the change: 1.
The company is mainly engaged in the research and development, production and sales of Chinese proprietary drugs, chemical preparations and
chemical APIs.
2.
Cephalexin capsules have passed the consistency evaluation of generic drugs, and this product is one of the key products of anti-infective drugs, which is mainly used for the treatment of acute tonsillitis, angina, sinusitis, bronchitis, pneumonia and other respiratory infections, otitis media, urinary tract infections and skin and soft tissue infections caused by sensitive bacteria
.
3.
The company's cough suppressant tablet products have a long history of nearly 100 years, and the secret recipe of the product has been selected as the cultural protection heritage
of Lingnan traditional Chinese medicine.
4.
The company plans to invest 100 million yuan to establish Guangdong Temei Health Technology Industry Co.
, Ltd.
, and the company to be established is the large health industry investment and operation platform of Teyi Pharmaceutical Group, and its development direction includes the development and investment
of medical beauty services.
Analysts believe that under multiple positives, the stock may continue to have high momentum in the future
.
Among them, especially under
the marginal favorable policy of the traditional Chinese medicine industry.
It is reported that on November 11, China issued a relevant notice, requiring attention to the unique advantages of traditional Chinese medicine and the reserve
of effective traditional Chinese medicine prescriptions.
This is expected to drive the continued strengthening of the Chinese medicine sector in the near future, which is expected to benefit the development of the Chinese medicine industry and related companies in the long term
.
Among them, naturally it also includes Special One Pharmaceutical
.
In fact, at present, capital is also focusing on the special pharmaceutical industry
.
Specifically, from November 12 to 19, Teyi Pharmaceutical was surveyed by a total of 63 institutions
.
According to the research list, in addition to many public offerings such as Cinda Australasia Fund, Invesco Great Wall Fund, Harvest Fund, and Huatai Berry Fund, well-known private placements such as Tongfeng Investment, Convergence Capital, and Yude Investment also gathered together
.
In general, the current upward trend of the pharmaceutical sector is clear, and the traditional Chinese medicine sector will accelerate its development with the continuous support of policies, and at the same time, it is expected to be beneficial to the development of
industries and related companies in the long term.
Disclaimer: Under no circumstances does the information or opinions expressed herein constitute investment advice
to anyone.